A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC	Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder	Recruiting	Phase 1	2026-08-14		NCT06826768

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
M.D. Anderson Cancer Center	1145
Regeneron Pharmaceuticals	238

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The University of Texas M. D. Anderson Cancer Center	Houston	United States	88

Clinical trials